J. Makielski, C. Valdivia
May 1, 2006
Citations
1
Influential Citations
29
Citations
Journal
British Journal of Pharmacology
Abstract
Ranolazine is a new antianginal drug approved for clinical use in the United States in January 2006. A study published in this same issue of the British Journal of Pharmacology characterizes ranolazine block of late sodium current caused by the long QT syndrome 3 mutations. This commentary discusses the implications of that study and the background and implications for block of late cardiac sodium current in general.